If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Trading Update

7 Nov 2016 07:00

RNS Number : 4343O
Ideagen PLC
07 November 2016
 

7 November 2016

Ideagen plc

("Ideagen" or the "Company")

 

Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, today provides an update on trading for the six months ended 31 October 2016.

 

The Board is pleased to report that trading has remained strong in the first half of the financial year.

 

Revenue and adjusted EBITDA are expected to show a significant increase over the same period last year through a combination of organic growth and the acquisition of Covalent. The Group expects to report organic revenue growth of approximately 16% together with a small contribution from Covalent which was acquired in August 2016. The integration of Covalent is now complete and the Company expects an increased level of contribution in the second half. Consequently, the Company continues to trade in line with market expectations for the full year to 30 April 2017.

 

Cash generation in the period was strong and the Company maintains a robust balance sheet with no debt. The cash balance at the period end was £4.8 million (30 April 2016: £6.3 million), after the payment of £3.8 million for acquisitions and associated costs.

 

David Hornsby, Chief Executive Officer of Ideagen, commented: "This has been a good start to the financial year. Strong trading has been driven by demand across all key vertical markets and continued momentum with our cloud-based Enlighten solution. The market opportunity remains large and long term, and consequently, the Board is optimistic about the Group's continued growth prospects."

 

 

Enquiries:

Ideagen plc

Tel: 01629 699100

David Hornsby, Chief Executive

Graeme Spenceley, Finance Director

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews / James Thompson (Corporate Finance)

Stephen Norcross (Corporate Broking)

Alma PR

Tel: 020 8004 4218

Hilary Buchanan

Josh Royston

About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.LN). Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in eGRC (Enterprise Governance, Risk and Compliance) and Healthcare solutions for organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete content lifecycle solutions that enable organisations to meet their Regulatory and Quality Compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 2,200 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVZLFBQFFFFBQ
Date   Source Headline
14th Oct 20215:46 pmRNSIssue of new shares under the SIP
14th Oct 20217:00 amRNSSale of Pentana Compliance
11th Oct 20212:25 pmRNSNotice of AGM
1st Oct 20213:15 pmRNSTotal Voting Rights
1st Oct 20217:00 amRNSChange of Auditor
24th Sep 20219:37 amRNSIssue of Shares, PDMR Dealing & TVR
13th Sep 20214:50 pmRNSExercise of Options and Total Voting Rights
10th Sep 20216:05 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSTotal Voting Rights
31st Aug 20219:32 amRNSHolding(s) in Company
26th Aug 20217:00 amRNSPDMR Dealing and Total Voting Rights
11th Aug 20212:02 pmRNSIssue of new shares under the SIP and TVR
11th Aug 20217:00 amRNSExercise of Options and Total Voting Rights
23rd Jul 20214:54 pmRNSPDMR Dealing and Total Voting Rights
22nd Jul 20217:00 amRNSFinal Results
20th Jul 20212:03 pmRNSIssue of new shares under the SIP
19th Jul 20217:00 amRNSTwo highly complementary strategic acquisitions
15th Jul 20214:17 pmRNSExercise of share options and Total Voting Rights
16th Jun 20217:00 amRNSIssue of new shares under the SIP
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:36 pmRNSPrice Monitoring Extension
21st May 20217:00 amRNSDirector/PDMR Shareholding
13th May 20217:00 amRNSPre-Close Trading Update and Board Change
28th Apr 20217:00 amRNSDirector Dealings and Total Voting Rights
14th Apr 202112:40 pmRNSIssue of Shares, PDMR Dealing & TVR
16th Mar 20213:33 pmRNSIssue of new shares under the SIP and TVR
9th Mar 20217:00 amRNSAcquisition of Qualtrax
26th Feb 20211:49 pmRNSHolding(s) in Company
25th Feb 20214:00 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSHolding(s) in Company
23rd Feb 20217:00 amRNSPDMR Dealing and Total Voting Rights
16th Feb 20215:15 pmRNSIssue of Equity & Total Voting Rights
12th Feb 20217:00 amRNSDirector/PDMR Dealings
3rd Feb 20219:35 amRNSExtension to 2018 LTIP Awards
26th Jan 20217:00 amRNSSuccession of Chairman
26th Jan 20217:00 amRNSUnaudited Interim Results
25th Jan 20214:26 pmRNSH1 Results Presentation
22nd Jan 20217:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
30th Dec 20207:21 amRNSCompletion of Huddle Acquisition
23rd Dec 202011:30 amRNSAcquisition of Huddle
22nd Dec 20202:04 pmRNSHolding(s) in Company
18th Dec 202012:56 pmRNSIssue of Shares & Director/PDMR Shareholding
9th Dec 20207:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20204:53 pmRNSPrimaryBid.com Offer
8th Dec 20204:50 pmRNSProposed Fundraise of £48.7 million
20th Nov 20203:40 pmRNSIssue of Equity, PDMR Dealing and TVR
17th Nov 202012:05 pmRNSChange of Registered Office
13th Nov 20203:51 pmRNSPDMR Shareholding and Exercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.